-5%
Dasacent is a medication primarily used for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in both adult and pediatric patients.Â
- Adults:
- Newly diagnosed Ph+ CML in chronic phase.
- Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
- Ph+ ALL with resistance or intolerance to prior therapy.
- Pediatric patients (1 year and older):
- Ph+ CML in chronic phase.
- Newly diagnosed Ph+ ALL in combination with chemotherapy.
- Mechanism of Action: Dasatinib inhibits several kinases including BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ. This inhibition helps overcome Imatinib resistance and targets various signaling pathways involved in leukemia progression.
- Absorption: Peak plasma concentrations are reached between 0.5 to 6 hours after oral administration.
- Metabolism: Primarily metabolized by CYP3A4, with minor contributions from other enzymes like FMO-3 and UGT.
- Excretion: Mostly excreted in the feces, with only 4% excreted in urine.
